The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke "EUREKA"


Phase 3 Results N/A

Summary of Purpose

It is anticipated that 548 subjects will be recruited from approximately 27 centres in South Korea. This is an investigator-sponsored, double-blind, placebo-controlled, randomized, multi-centre study to assess the effects of rosuvastatin 20 mg compared to placebo in acute ischemic stroke patients, with the first... Trial Stopped: Slow enrollment

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 November 2014.

1 Aug 2010 26 May 2011 1 Apr 2013 1 Apr 2013 1 Nov 2014 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment